SV2017005419A - Triazolopirazinonas como inhibidores de pde1 - Google Patents

Triazolopirazinonas como inhibidores de pde1

Info

Publication number
SV2017005419A
SV2017005419A SV2017005419A SV2017005419A SV2017005419A SV 2017005419 A SV2017005419 A SV 2017005419A SV 2017005419 A SV2017005419 A SV 2017005419A SV 2017005419 A SV2017005419 A SV 2017005419A SV 2017005419 A SV2017005419 A SV 2017005419A
Authority
SV
El Salvador
Prior art keywords
triazolopirazinonas
pde1 inhibitors
pde1
inhibitors
disorders
Prior art date
Application number
SV2017005419A
Other languages
English (en)
Inventor
Jan Kehler
Lars Kyhn Rasmusse
Mikkel Jessing
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SV2017005419A publication Critical patent/SV2017005419A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA TRIAZOLOPIRAZINONAS COMO INHIBIDORES DE PDE1 Y SU USO COMO UN MEDICAMENTO, EN PARTICULAR PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS Y TRASTORNOS PSIQUI�TRICOS
SV2017005419A 2014-10-10 2017-03-31 Triazolopirazinonas como inhibidores de pde1 SV2017005419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400582 2014-10-10
PCT/EP2015/073417 WO2016055618A1 (en) 2014-10-10 2015-10-09 Triazolopyrazinones as pde1 inhibitors

Publications (1)

Publication Number Publication Date
SV2017005419A true SV2017005419A (es) 2017-06-07

Family

ID=58698606

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005419A SV2017005419A (es) 2014-10-10 2017-03-31 Triazolopirazinonas como inhibidores de pde1

Country Status (25)

Country Link
US (1) US10150771B2 (es)
EP (1) EP3204387B1 (es)
JP (1) JP6596489B2 (es)
KR (1) KR20170066417A (es)
CN (1) CN106715438B (es)
AR (1) AR102227A1 (es)
AU (1) AU2015329898A1 (es)
BR (1) BR112017006940A2 (es)
CA (1) CA2961986A1 (es)
CL (1) CL2017000817A1 (es)
CO (1) CO2017002708A2 (es)
DO (1) DOP2017000080A (es)
EA (1) EA201790575A1 (es)
EC (1) ECSP17018120A (es)
ES (1) ES2735733T3 (es)
IL (1) IL251420A0 (es)
MX (1) MX2017004510A (es)
PE (1) PE20180024A1 (es)
PH (1) PH12017500621A1 (es)
RU (1) RU2017111888A (es)
SG (1) SG11201702874YA (es)
SV (1) SV2017005419A (es)
TN (1) TN2017000099A1 (es)
TW (1) TW201629064A (es)
WO (1) WO2016055618A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之***並吡酮
TW201643167A (zh) * 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20170164A1 (ar) * 2016-08-25 2019-01-30 Lilly Co Eli مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
ES2967489T3 (es) * 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
EP3532053A1 (en) 2016-10-28 2019-09-04 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
WO2018078038A1 (en) * 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
AR112457A1 (es) * 2017-08-02 2019-10-30 Lilly Co Eli Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona
JP7254078B2 (ja) 2017-11-27 2023-04-07 ダート・ニューロサイエンス・エルエルシー Ｐｄｅ１阻害剤としての置換フラノピリミジン化合物
AR113926A1 (es) * 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
HUE057202T2 (hu) * 2017-12-14 2022-04-28 H Lundbeck As Kombinációs kezelések 1H-pirazolo[4,3-b]piridinek alkalmazásával
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
TW201927784A (zh) * 2017-12-20 2019-07-16 丹麥商Ｈ 朗德貝克公司 作為pde1抑制劑之大環
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
US11453673B2 (en) * 2018-02-06 2022-09-27 Eli Lilly And Company Substituted [1,2,4]triazolo[4,3-a]pyrazines as phosphodiesterase inhibitors

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
JP2006525966A (ja) 2003-05-09 2006-11-16 バイエル・ヘルスケア・アクチェンゲゼルシャフト ６−シクリルメチル−および６−アルキルメチル置換ピラゾロピリミジン類
WO2006068978A2 (en) 2004-12-21 2006-06-29 Takeda Pharmaceutial Company Limited Dipeptidyl peptidase inhibitors
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
NZ580904A (en) 2007-05-11 2012-02-24 Pfizer Amino-heterocyclic compounds for inhibiting pde9
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20110383A1 (es) 2008-09-08 2011-07-15 Boehringer Ingelheim Int Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
SG171777A1 (en) 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US9434730B2 (en) * 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
CN103313988B (zh) 2010-09-20 2016-06-08 论坛医药有限公司 咪唑并三嗪酮化合物
EP2619204A4 (en) * 2010-09-21 2014-08-27 Merck Sharp & Dohme TRIAZOLOPYRAZINONES AS ANTAGONISTS OF P2X7 RECEPTORS
US10561656B2 (en) * 2011-06-10 2020-02-18 Intra-Cellular Therapies, Inc. Organic compounds
JP2015531401A (ja) 2011-10-10 2015-11-02 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノン骨格を有するｐｄｅ９ｉ
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
EP2861603B1 (en) 2012-06-18 2018-12-19 Dart NeuroScience (Cayman) Ltd 6-Benzyl-6H-pyrido[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-one and 6-benzyl-[1,2,4]triazolo[1,5-c]pteridin-5(6H)-one derivatives as PDE1 inhibitors for treating e.g. neurological disorders
JP6437519B2 (ja) 2013-03-15 2018-12-12 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之***並吡酮
JP2018508555A (ja) 2015-03-16 2018-03-29 大日本住友製薬株式会社 二環性イミダゾロ誘導体
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
ES2967489T3 (es) 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
EP3532053A1 (en) 2016-10-28 2019-09-04 H. Lundbeck A/S Combination treatments comprising administration of imidazopyrazinones
WO2018078038A1 (en) 2016-10-28 2018-05-03 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders

Also Published As

Publication number Publication date
JP6596489B2 (ja) 2019-10-23
PH12017500621A1 (en) 2017-09-25
EP3204387B1 (en) 2019-06-12
KR20170066417A (ko) 2017-06-14
BR112017006940A2 (pt) 2018-01-09
US20170298072A1 (en) 2017-10-19
CN106715438B (zh) 2019-04-12
TN2017000099A1 (en) 2018-07-04
AU2015329898A1 (en) 2017-03-30
IL251420A0 (en) 2017-05-29
CL2017000817A1 (es) 2017-11-03
EP3204387A1 (en) 2017-08-16
CN106715438A (zh) 2017-05-24
WO2016055618A1 (en) 2016-04-14
US10150771B2 (en) 2018-12-11
CA2961986A1 (en) 2016-04-14
DOP2017000080A (es) 2017-05-15
TW201629064A (zh) 2016-08-16
JP2017530173A (ja) 2017-10-12
CO2017002708A2 (es) 2017-06-30
ECSP17018120A (es) 2017-08-31
PE20180024A1 (es) 2018-01-09
MX2017004510A (es) 2017-06-28
AR102227A1 (es) 2017-02-15
RU2017111888A (ru) 2018-11-12
ES2735733T3 (es) 2019-12-20
EA201790575A1 (ru) 2017-07-31
SG11201702874YA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
SV2018005801A (es) 1h-pirazolo[4,3-b]piridinas como inhibidores de pde 1
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
DOP2016000152A (es) Quinazolin-thf-aminas como inhibidores de pde1.
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
ECSP16082599A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
DOP2016000179A (es) Hexahidrofuropirroles como inhibidores de pde1